166 filings
Page 5 of 9
8-K
dialz
3 Aug 17
Second Quarter 2017 Investor Update
12:00am
8-K
sesf0
2 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
x0pce
8 May 17
First Quarter 2017 Investor Update
12:00am
8-K
3sy nj00omx
18 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
w9qmt1w9zxk
30 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
jbs05eitg nh
21 Feb 17
Fourth Quarter and Full Year 2016 Investor Update
12:00am
8-K
wbv v4u7oiz7sg78r
1 Feb 17
Entry into a Material Definitive Agreement
12:00am
8-K
lrxkx8q d6
9 Jan 17
Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech
12:00am
8-K
67tt9
5 Jan 17
Termination of a Material Definitive Agreement
12:00am
8-K
zqyptata3yvrsn
4 Jan 17
Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
12:00am
8-K
ppg pul1au6l4e
3 Nov 16
Third Quarter 2016 Investor Update
12:00am
8-K
gqoarp sbk3o9
26 Sep 16
Ironwood Closes $150 Million Debt Refinancing
12:00am
8-K
v9fw43 k5
4 Aug 16
Second Quarter 2016 Investor Update
12:00am
8-K
9ie683it9d3chyrab1en
3 Jun 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
bjn2gxqo
3 Jun 16
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
12:00am
8-K
1suezmacbk6 irwy
9 May 16
First Quarter 2016 Investor Update
12:00am
8-K
q71opyss4n1whic9
26 Apr 16
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad
12:00am
8-K
im2i j0doe1
7 Apr 16
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to
12:00am
8-K
sz7vb zej6rwpq5px
18 Feb 16
Fourth Quarter and Full Year 2015 Investor Update
12:00am
8-K
9wqpy8kkc25zt32q8hz
11 Jan 16
Ironwood Pharmaceuticals Details Strategy to Build Top-Performing Commercial Biotechnology Company
12:00am